Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Neurocrine Biosciences Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.48, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). Which is the better fit depends on your goals.
| BOTZ | NBIX | |
|---|---|---|
52-Week High | $41.63 | $185.50 |
52-Week Low | $31.99 | $123.10 |
Market Cap | — | $16.76B |
Sector | — | Health |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.61, up 1.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, offering exposure to global leaders in automation. Recent news highlights its role in the expanding AI and robotics theme, with comparisons to peers like ARKQ and ROBO. A small dividend is scheduled for 2026.
Outlook is positive due to growth in AI and robotics adoption, but risks include high valuation sensitivity and sector competition. Investors should weigh the thematic growth potential against market volatility and the ETF's expense structure.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
